Oncostatin M/OSM Antibody (17001.31) [Janelia Fluor® 549]

• Reactivity: Hu, Mu(-)
• Applications: IHC, B/N
• Clone: 17001.31
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Janelia Fluor 549

Oncostatin M/OSM Antibody (17001.31) [Janelia Fluor® 549] Summary

• Immunogen: Recombinant full length protein (Human) expressed in E. coli.
• Localization: Secreted
• Specificity: Does not cross-react with recombinant human IL-6, IL-11, CNTF, LIF and recombinant mouse OSM.
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Gene: OSM
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • Block/Neutralize
  • Immunohistochemistry
• Application Notes: Optimal dilution of this antibody should be experimentally determined.

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark.
• Buffer: 50mM Sodium Borate
• Preservative: 0.05% Sodium Azide
• Purity: Protein A purified

Notes

Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.

Alternate Names for Oncostatin M/OSM Antibody (17001.31) [Janelia Fluor® 549]

• MGC20461
• oncostatin M
• oncostatin-M
• OSM

Background

Oncostatin M is a 252 amino acid protein that is 28 kDa, acts as growth regulator inhibiting the proliferation of a number of tumor cell lines and stimulating the proliferation of AIDS-KS cells; regulates cytokine production, including IL-6, G-CSF and GM-CSF from endothelial cells; uses both type I OSM receptor (heterodimers composed of LIPR and IL6ST) and type II OSM receptor (heterodimers composed of OSMR and IL6ST), and is involved in the maturation of fetal hepatocytes, thereby promoting liver development and regeneration. This protein is being studied for its involvement in several diseases and disorders including arterial occlusive disease, peripheral arterial occlusive disease, leukemia, kaposi's sarcoma, abdominal aortic aneurysm, status epilepticus, primary cutaneous amyloidosis, aortic aneurysm, bullous pemphigoid, neonatal jaundice, cutaneous malignant melanoma, plasmacytoma, systemic mastocytosis, mastocytosis, cervical squamous cell carcinoma, systemic lupus erythematosus, allergic rhinitis, squamous cell carcinoma, and lupus erythematosus. The protein has been linked to immune response IL-3 activation and signaling pathway, immune response oncostatin M signaling via JAK-Stat in human cells, development thrombopoetin signaling via JAK-STAT pathway, immune response Oncostatin M signaling via MAPK in human cells, MAPK signaling, endothelin-1 signaling pathway, molecular mechanisms of cancer, antioxidant action of vitamin-C, and Rho Family GTPases pathways where it interacts with IL6ST, TNNT1, LIFR, COL4A4, and COL4A6.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Oncostatin M/OSM Antibody (NB120-10842JF549)(1)

Publication using NB120-10842JF549

• Varn FS, Johnson KC, Martinek J Et al. Glioma progression is shaped by genetic evolution and microenvironment interactions Cell 2022-06-01 [PMID: 35649412] (IHC-P, Human)
  
  Details:
  Citation using the Alexa Fluor 647 version of this antibody.

Bioinformatics

• Gene Symbol: OSM